Lupin receives FDA approval for biosimilar Armlupeg

Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs

Roche expands Veeva partnership with global rollout of AI-driven Vault CRM

Roche says the move marks a step forward in its digital transformation strategy

OSR Holdings moves towards major licensing deal for oral cancer immunotherapy

Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones

Global measles deaths plunge but cases surge, says WHO

In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic

Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection

Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy

Europe failing to diagnose HIV early, threatening 2030 AIDS target

Amrutanjan re-launches its iconic yellow balm

Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'

Innoxel Lifesciences completes EU GMP inspection by Belgium's FAMHP

The audit was completed with zero critical and zero major observations

Lupin Foundation bags CRISIL's Highest VO 1A rating for Excellence in Social Responsibility

This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility